EANS-News: AGENNIX AG / Agennix AG Raises Approximately EUR 76 Million in Net Proceeds in Capital Increase

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital measures

Heidelberg (euro adhoc) - Proceeds expected to enable Company to
obtain topline data in Phase III non-small cell lung cancer trial
with lead product candidate oral talactoferrin

Planegg/Munich (Germany), October 1, 2010 - Agennix AG (Frankfurt
Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) today
announced that the Company has raised approximately EUR 76 million in
net proceeds in its capital increase via participation from both new
and existing shareholders. The execution of the capital increase is
based on the resolution passed at the Company´s annual general
meeting on May 25, 2010 to issue 20,588,705 new shares, which will
result in a total of 41,413,846 shares issued and outstanding.
Subscription rights have been granted to the shareholders. The
subscription price was EUR 3.81 per share.

"We are very pleased to be able to successfully complete this
financing," said Torsten Hombeck, Ph.D., Chief Financial Officer of
Agennix. "The funds raised are expected to enable us to obtain
topline data in the ongoing Phase III FORTIS-M trial with oral
talactoferrin in non-small cell lung cancer. As of September 30
2010, 443 patients or approximately 62% of a total 720 patients were
enrolled in FORTIS-M, and we continue to expect topline data from
this trial by the end of 2011."

Dr. Hombeck continued: "With funds raised in the offering, we also
plan to initiate a Phase III trial with talactoferrin in severe
sepsis, an area of major unmet medical need. This trial is expected
to start in early 2011. The money raised will also enable us to
continue other important activities, including additional R&D work
such as initiating a Phase I trial in hematological tumors with our
multi-targeted kinase inhibitor, RGB-286638, as well as expanding
production capacity for oral talactoferrin."

In the capital increase, approximately 29% of the 20,588,705 new
shares were subscribed in the rights offering and approximately 71%
of the shares were purchased by new institutional investors in a
private placement or by dievini Hopp BioTech holding GmbH & Co. KG
under a firm commitment agreement.

Following the completion of this offering, dievini will hold
approximately 59% of shares outstanding in Agennix. Dievini has
informed the Company that it has not yet received a decision from the
German Federal Financial Supervisory Authority (Bundesanstalt fuer
Finanzdienstleistungsaufsicht) (BaFin) regarding dievini´s
application for an exemption from the obligation to make a mandatory
tender offer. Dievini applied for this exemption in case it acquired
control of the Company in the meaning of Section 29 (2) of the German
Takeover Act through participation in the capital increase.

The entry of the capital increase in the commercial register of the
local court in Mannheim is expected to occur on or around October 4,
2010. The new shares will be listed on the Frankfurt Stock Exchange
and are expected to begin trading on or around October 5, 2010. The
Joint Global Coordinators for the transaction were Piper Jaffray Ltd.
and WestLB AG.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company´s most
advanced program is talactoferrin, an oral therapy that has
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing; the oral platinum-based compound
satraplatin; and a topical gel form of talactoferrin for diabetic
foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The
Company has three sites of operation: Planegg/Munich, Germany;
Princeton, New Jersey and Houston, Texas. For additional information,
please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

This press release is not for distribution, directly or indirectly,
in or into the United States (including its territories and
possessions, any State of the United States and the District of
Columbia). These materials do not constitute or form a part of any
offer or solicitation to purchase or subscribe for securities in the
United States of America. The shares in Agennix AG (the "Shares")
mentioned herein may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S.
Securities Act of 1933, as amended (the "Securities Act").

The Shares have not been, and will not be, registered under the
Securities Act and will not be offered or sold in the United States,
except on the basis of applicable exemptions from registration. There
will be no public offering of securities in the United States.

For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG

Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Investor Relations & Corporate Communications

Tel.: +49 (0) 89 8565 2693

E-Mail: ir@agennix.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade